Skip to content
2000
image of A Pharmacovigilance Update about Drug-induced Depression and Suicidal Behaviors

Abstract

Medication is one of the pathogenic factors triggering mental disorders such as depression/suicidal behavior. Antiepileptic drugs, antibiotics and hormones may increase the risk of depression or suicidal behavior in patients. We provide an overview of the clinical symptoms, susceptible populations and major drugs that cause drug-induced depression/suicidal behavior. High-level literature such as meta-analyses or clinical trials were used to demonstrate the correlation between commonly used medicines and depression/suicidal behavior. We also pay attention to the severity of adverse drug reactions caused by different drugs of the same type, whether patients with drug-induced depression need to be treated with antidepressants, and which type of antidepressant should be used, providing a basis for clinicians to optimize treatment strategies.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cprr/10.2174/0126660822361079250329171531
2025-04-10
2025-09-09

  • From This Site

    /content/journals/cprr/10.2174/0126660822361079250329171531
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Castaldelli-Maia J.M. Bhugra D. Analysis of global prevalence of mental and substance use disorders within countries: Focus on sociodemographic characteristics and income levels. Int. Rev. Psychiatry 2022 34 1 6 15 10.1080/09540261.2022.2040450 35584016
    [Google Scholar]
  2. Agid O. Kohn Y. Lerer B. Environmental stress and psychiatric illness. Biomed Pharmacother 2000 54 3 135 141 10.1016/S0753‑3322(00)89046‑0
    [Google Scholar]
  3. Sapolsky R.M. Gene therapy for psychiatric disorders. Am. J. Psychiatry 2003 160 2 208 220 10.1176/appi.ajp.160.2.208 12562564
    [Google Scholar]
  4. Lecic-Tosevski D. Draganic-Gajic S. Pejovic-Milovancevic M. Popovic-Deusic S. Christodoulou N. Botbol M. Child is father of the man: Child abuse and development of future psychopathology. Psychiatriki 2014 25 3 185 191 25367662
    [Google Scholar]
  5. Quadros L.C.M. Quevedo L.A. Gonçalves H.D. Horta B.L. Motta J.V.S. Gigante D.P. Common Mental Disorders and Contemporary Factors: 1982 Birth Cohort. Rev. Bras. Enferm. 2020 73 1 e20180162 10.1590/0034‑7167‑2018‑0162 32049231
    [Google Scholar]
  6. Banasr M. Dwyer J.M. Duman R.S. Cell atrophy and loss in depression: Reversal by antidepressant treatment. Curr. Opin. Cell Biol. 2011 23 6 730 737 10.1016/j.ceb.2011.09.002 21996102
    [Google Scholar]
  7. Montastruc F. Taillefer de Laportaliere T. Drug-induced psychiatric disorders: A pharmacovigilance update. Therapie 2024 79 2 173 179 10.1016/j.therap.2023.09.007 37957053
    [Google Scholar]
  8. Wang G. Si T.M. Li L. Fang Y. Wang C.X. Wang L.N. Tan K.H.X. Ettrup A. Eriksen H.L.F. Luo S. Ge L. Cognitive symptoms in major depressive disorder: Associations with clinical and functional outcomes in a 6-month, non-interventional, prospective study in China. Neuropsychiatr. Dis. Treat. 2019 15 1723 1736 10.2147/NDT.S195505 31308667
    [Google Scholar]
  9. O’Connor E. Henninger M. Perdue L.A. Coppola E.L. Thomas R. Gaynes B.N.U.S. Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews. 2023
    [Google Scholar]
  10. Herrman H. Patel V. Kieling C. Berk M. Buchweitz C. Cuijpers P. Furukawa T.A. Kessler R.C. Kohrt B.A. Maj M. McGorry P. Reynolds C.F. III Weissman M.M. Chibanda D. Dowrick C. Howard L.M. Hoven C.W. Knapp M. Mayberg H.S. Penninx B.W.J.H. Xiao S. Trivedi M. Uher R. Vijayakumar L. Wolpert M. Time for united action on depression: A Lancet–World Psychiatric Association Commission. Lancet 2022 399 10328 957 1022 10.1016/S0140‑6736(21)02141‑3 35180424
    [Google Scholar]
  11. Adverse Drug Reactions Advisory C. Depression - Could it be the drug? Aust Adv Drug Reactions Bull. 1998 17 1 3
    [Google Scholar]
  12. Larsson J. Antidepressants and suicide among young women in Sweden 1999–2013. Int. J. Risk Saf. Med. 2017 29 1-2 101 106 10.3233/JRS‑170739 28885220
    [Google Scholar]
  13. Qato D.M. Ozenberger K. Olfson M. Prevalence of Prescription Medications With Depression as a Potential Adverse Effect Among Adults in the United States. JAMA 2018 319 22 2289 2298 10.1001/jama.2018.6741 29896627
    [Google Scholar]
  14. Patten S.B. Love E.J. Drug-Induced Depression. Drug Saf. 1994 10 3 203 219 10.2165/00002018‑199410030‑00003 7913812
    [Google Scholar]
  15. Patten S.B. Love E.J. Drug-Induced Depression. Psychother. Psychosom. 1997 66 2 63 73 10.1159/000289110 9097332
    [Google Scholar]
  16. Patten S.B. Barbui C. Drug-induced depression: A systematic review to inform clinical practice. Psychother. Psychosom. 2004 73 4 207 215 10.1159/000077739 15184715
    [Google Scholar]
  17. Jørgensen T.S.H. Wium-Andersen I.K. Wium-Andersen M.K. Jørgensen M.B. Prescott E. Maartensson S. Kragh-Andersen P. Osler M. Incidence of Depression After Stroke, and Associated Risk Factors and Mortality Outcomes, in a Large Cohort of Danish Patients. JAMA Psychiatry 2016 73 10 1032 1040 10.1001/jamapsychiatry.2016.1932 27603000
    [Google Scholar]
  18. Lu J. Xu X. Huang Y. Li T. Ma C. Xu G. Yin H. Xu X. Ma Y. Wang L. Huang Z. Yan Y. Wang B. Xiao S. Zhou L. Li L. Zhang Y. Chen H. Zhang T. Yan J. Ding H. Yu Y. Kou C. Shen Z. Jiang L. Wang Z. Sun X. Xu Y. He Y. Guo W. Jiang L. Li S. Pan W. Wu Y. Li G. Jia F. Shi J. Shen Z. Zhang N. Prevalence of depressive disorders and treatment in China: A cross-sectional epidemiological study. Lancet Psychiatry 2021 8 11 981 990 10.1016/S2215‑0366(21)00251‑0 34559991
    [Google Scholar]
  19. Abdelhafez M.A. Ahmed K.M. Ahmed N.M. Ismail M. Mohd Daud M.N.B. Ping N.P.T. Eldiasty A. Amri M.F.B. Jeffree M.S. Kadir F. pg Baharuddin D.M. Bolong M.F.B. Hayati F. BtAzizan N. Sumpat D. Syed Abdul Rahim S.S. Abdel Malek E.H. Psychiatric illness and pregnancy: A literature review. Heliyon 2023 9 11 e20958 10.1016/j.heliyon.2023.e20958 37954333
    [Google Scholar]
  20. Yasuma N. Narita Z. Sasaki N. Obikane E. Sekiya J. Inagawa T. Nakajima A. Yamada Y. Yamazaki R. Matsunaga A. Saito T. Watanabe K. Imamura K. Kawakami N. Nishi D. Antenatal psychological intervention for universal prevention of antenatal and postnatal depression: A systematic review and meta-analysis. J. Affect. Disord. 2020 273 231 239 10.1016/j.jad.2020.04.063 32421608
    [Google Scholar]
  21. Selected 2016-2022 maternal and child health (MCH) indicators. 2022 Available from: https://www.cdc.gov/prams/php/data-research/mch-indicators-by-site.html
  22. Berk M. Williams L.J. Jacka F.N. O’Neil A. Pasco J.A. Moylan S. Allen N.B. Stuart A.L. Hayley A.C. Byrne M.L. Maes M. So depression is an inflammatory disease, but where does the inflammation come from? BMC Med. 2013 11 1 200 10.1186/1741‑7015‑11‑200 24228900
    [Google Scholar]
  23. Maes M. Yirmyia R. Noraberg J. Brene S. Hibbeln J. Perini G. Kubera M. Bob P. Lerer B. Maj M. The inflammatory & neurodegenerative (I&ND) hypothesis of depression: Leads for future research and new drug developments in depression. Metab. Brain Dis. 2009 24 1 27 53 10.1007/s11011‑008‑9118‑1 19085093
    [Google Scholar]
  24. Comorbid depression in medical diseases. Nat. Rev. Dis. Primers 2020 6 1 70 10.1038/s41572‑020‑0211‑z 32820160
    [Google Scholar]
  25. Das J. G K R. Post stroke depression: The sequelae of cerebral stroke. Neurosci. Biobehav. Rev. 2018 90 104 114 10.1016/j.neubiorev.2018.04.005 29656030
    [Google Scholar]
  26. Braund T.A. Tillman G. Palmer D.M. Gordon E. Rush A.J. Harris A.W.F. Antidepressant side effects and their impact on treatment outcome in people with major depressive disorder: An iSPOT-D report. Transl. Psychiatry 2021 11 1 417 10.1038/s41398‑021‑01533‑1 34349116
    [Google Scholar]
  27. Whittington C.J. Kendall T. Fonagy P. Cottrell D. Cotgrove A. Boddington E. Selective serotonin reuptake inhibitors in childhood depression: Systematic review of published versus unpublished data. The Lancet 2004 363 9418 1341 1345 10.1016/S0140‑6736(04)16043‑1
    [Google Scholar]
  28. Fergusson D. Doucette S. Glass K.C. Shapiro S. Healy D. Hebert P. Hutton B. Association between suicide attempts and selective serotonin reuptake inhibitors: Systematic review of randomised controlled trials. BMJ 2005 330 7488 396 10.1136/bmj.330.7488.396 15718539
    [Google Scholar]
  29. Gunnell D. Saperia J. Ashby D. Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: Meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA’s safety review. BMJ 2005 330 7488 385 10.1136/bmj.330.7488.385 15718537
    [Google Scholar]
  30. Laughren T. http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4272b1-01-FDA.pdf 2006
  31. Geddes J.R. Barbui C. Cipriani A. Risk of suicidal behaviour in adults taking antidepressants. BMJ 2009 339 aug11 2 b3066 10.1136/bmj.b3066 19671934
    [Google Scholar]
  32. Sharma T. Guski L.S. Freund N. Gøtzsche P.C. Suicidality and aggression during antidepressant treatment: Systematic review and meta-analyses based on clinical study reports. BMJ 2016 352 i65 10.1136/bmj.i65 26819231
    [Google Scholar]
  33. Hammad T.A. Laughren T. Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch. Gen. Psychiatry 2006 63 3 332 339 10.1001/archpsyc.63.3.332 16520440
    [Google Scholar]
  34. Mindham R.H.S. Marsden C.D. Parkes J.D. Psychiatric symptoms during L -dopa therapy for Parkinson’s disease and their relationship to physical disability. Psychol. Med. 1976 6 1 23 33 10.1017/S0033291700007467 778880
    [Google Scholar]
  35. Hetrick S.E. McKenzie J.E. Bailey A.P. Sharma V. Moller C.I. Badcock P.B. Cox G.R. Merry S.N. Meader N. New generation antidepressants for depression in children and adolescents: A network meta-analysis. Cochrane Database Syst. Rev. 2021 5 5 CD013674 [PMID: 34029378]. 34029378
    [Google Scholar]
  36. Schmitz B. Effects of antiepileptic drugs on mood and behavior. Epilepsia 2006 47 s2 Suppl. 2 28 33 10.1111/j.1528‑1167.2006.00684.x 17105456
    [Google Scholar]
  37. Kuehn B.M. FDA warns of adverse events linked to smoking cessation drug and antiepileptics. JAMA 2008 299 10 1121 1122 10.1001/jama.299.10.1121 18334683
    [Google Scholar]
  38. US Food and Drug Administration FDA alerts health care providers to risk of suicidal thoughts and behavior with antiepileptic medications. 2009 www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm100200.htm
    [Google Scholar]
  39. Andersohn F. Schade R. Willich S.N. Garbe E. Use of antiepileptic drugs in epilepsy and the risk of self-harm or suicidal behavior. Neurology 2010 75 4 335 340 10.1212/WNL.0b013e3181ea157e 20660863
    [Google Scholar]
  40. Chen B. Choi H. Hirsch L.J. Katz A. Legge A. Buchsbaum R. Detyniecki K. Psychiatric and behavioral side effects of antiepileptic drugs in adults with epilepsy. Epilepsy Behav 2017 76 24 31
    [Google Scholar]
  41. Li J. Sun M. Wang X. The adverse-effect profile of lacosamide. Expert Opin. Drug Saf. 2020 19 2 131 138 10.1080/14740338.2020.1713089 31914330
    [Google Scholar]
  42. Canevini M.P. De Sarro G. Galimberti C.A. Gatti G. Licchetta L. Malerba A. Muscas G. La Neve A. Striano P. Perucca E. SOPHIE Study Group Relationship between adverse effects of antiepileptic drugs, number of coprescribed drugs, and drug load in a large cohort of consecutive patients with drug‐refractory epilepsy. Epilepsia 2010 51 5 797 804 10.1111/j.1528‑1167.2010.02520.x 20545754
    [Google Scholar]
  43. Mula M. Sander J.W. Suicidal ideation in epilepsy and levetiracetam therapy. Epilepsy Behav 2007 11 1 130 132 10.1016/j.yebeh.2007.04.008
    [Google Scholar]
  44. Cramer J.A. De Rue K. Devinsky O. Edrich P. Trimble M.R. A systematic review of the behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials. Epilepsy Behav 2003 4 2 124 132 10.1016/S1525‑5050(03)00005‑2
    [Google Scholar]
  45. Biton V. Gil-Nagel A. Isojarvi J. Doty P. Hebert D. Fountain N.B. Safety and tolerability of lacosamide as adjunctive therapy for adults with partial-onset seizures: Analysis of data pooled from three randomized, double-blind, placebo-controlled clinical trials. Epilepsy Behav 2015 52 Pt A 119 127
    [Google Scholar]
  46. Ben-Menachem E. Biton V. Jatuzis D. Abou-Khalil B. Doty P. Rudd G.D. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia 2007 48 7 1308 1317 10.1111/j.1528‑1167.2007.01188.x 17635557
    [Google Scholar]
  47. Hong Z. Inoue Y. Liao W. Meng H. Wang X. Wang W. Zhou L. Zhang L. Du X. Tennigkeit F. Efficacy and safety of adjunctive lacosamide for the treatment of partial-onset seizures in Chinese and Japanese adults: A randomized, double-blind, placebo-controlled study. Epilepsy Res. 2016 127 267 275 10.1016/j.eplepsyres.2016.08.032 27669155
    [Google Scholar]
  48. Baulac M. Byrnes W. Williams P. Borghs S. Webster E. De Backer M. Dedeken P. Lacosamide and sodium channel-blocking antiepileptic drug cross-titration against levetiracetam background therapy. Acta Neurol. Scand. 2017 135 4 434 441 10.1111/ane.12691 27714769
    [Google Scholar]
  49. Goodarzi Z. Mrklas K.J. Roberts D.J. Jette N. Pringsheim T. Holroyd-Leduc J. Detecting depression in Parkinson disease. Neurology 2016 87 4 426 437 10.1212/WNL.0000000000002898 27358339
    [Google Scholar]
  50. Eskow Jaunarajs K.L. Angoa-Perez M. Kuhn D.M. Bishop C. Potential mechanisms underlying anxiety and depression in Parkinson’s disease: Consequences of l-DOPA treatment. Neurosci. Biobehav. Rev. 2011 35 3 556 564 10.1016/j.neubiorev.2010.06.007 20615430
    [Google Scholar]
  51. Witt K. Daniels C. Herzog J. Lorenz D. Volkmann J. Reiff J. Mehdorn M. Deuschl G. Krack P. Differential effects of L-dopa and subthalamic stimulation on depressive symptoms and hedonic tone in Parkinson’s disease. J. Neuropsychiatry Clin. Neurosci. 2006 18 3 397 401 10.1176/jnp.2006.18.3.397 16963590
    [Google Scholar]
  52. Kim H.J. Park S.Y. Cho Y.J. Hong K.S. Cho J.Y. Seo S.Y. Lee D.H. Jeon B.S. Nonmotor symptoms in de novo Parkinson disease before and after dopaminergic treatment. J. Neurol. Sci. 2009 287 1-2 200 204 10.1016/j.jns.2009.07.026 19700173
    [Google Scholar]
  53. Choi C. Sohn Y.H. Lee J.H. Kim J.S. The effect of long-term levodopa therapy on depression level in de novo patients with Parkinson’s disease. J. Neurol. Sci. 2000 172 1 12 16 10.1016/S0022‑510X(99)00198‑7 10620654
    [Google Scholar]
  54. Pålhagen S.E. Carlsson M. Curman E. Wålinder J. Granérus A.K. Depressive illness in Parkinson’s disease – Indication of a more advanced and widespread neurodegenerative process? Acta Neurol. Scand. 2008 117 5 295 304 10.1111/j.1600‑0404.2007.00986.x 18279483
    [Google Scholar]
  55. Suzuki K. Miyamoto M. Miyamoto T. Okuma Y. Hattori N. Kamei S. Yoshii F. Utsumi H. Iwasaki Y. Iijima M. Hirata K. Correlation between depressive symptoms and nocturnal disturbances in Japanese patients with Parkinson’s disease. Parkinsonism Relat. Disord. 2009 15 1 15 19 10.1016/j.parkreldis.2008.02.002 18359262
    [Google Scholar]
  56. Weintraub D. Morales K.H. Duda J.E. Moberg P.J. Stern M.B. Frequency and correlates of co-morbid psychosis and depression in Parkinson’s disease. Parkinsonism Relat. Disord. 2006 12 7 427 431 10.1016/j.parkreldis.2006.03.006 16797214
    [Google Scholar]
  57. Imamura K. Okayasu N. Nagatsu T. The relationship between depression and regional cerebral blood flow in Parkinson’s disease and the effect of selegiline treatment. Acta Neurol. Scand. 2011 124 1 28 39 10.1111/j.1600‑0404.2010.01443.x 20880269
    [Google Scholar]
  58. Wang K. Liu Z.H. Li X.Y. Li Y.F. Li J.R. Hui J.J. Li J.X. Zhou J.W. Yi Z.M. Efficacy and safety of selegiline for the treatment of Parkinson’s disease: A systematic review and meta-analysis. Front. Aging Neurosci. 2023 15 1134472 10.3389/fnagi.2023.1134472 37113570
    [Google Scholar]
  59. Huang Y.H. Chen J.H. Loh E.W. Chan L. Hong C.T. The effect of monoamine oxidase-B inhibitors on the alleviation of depressive symptoms in Parkinson’s disease: Meta-analysis of randomized controlled trials. Ther. Adv. Psychopharmacol. 2021 11 2045125320985993 10.1177/2045125320985993 33520156
    [Google Scholar]
  60. Olanow C.W. Rascol O. Hauser R. Feigin P.D. Jankovic J. Lang A. Langston W. Melamed E. Poewe W. Stocchi F. Tolosa E. A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. N. Engl. J. Med. 2009 361 13 1268 1278 10.1056/NEJMoa0809335 19776408
    [Google Scholar]
  61. Reichenberg A. Gorman J.M. Dieterich D.T. Interferon-induced depression and cognitive impairment in hepatitis C virus patients: A 72 week prospective study. AIDS 2005 19 Suppl. 3 S174 S178 10.1097/01.aids.0000192087.64432.ae 16251815
    [Google Scholar]
  62. Schaefer M. Schwaiger M. Garkisch A.S. Pich M. Hinzpeter A. Uebelhack R. Heinz A. van Boemmel F. Berg T. Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. J. Hepatol. 2005 42 6 793 798 10.1016/j.jhep.2005.01.020 15885349
    [Google Scholar]
  63. Schäfer A. Wittchen H.U. Seufert J. Kraus M.R. Methodological approaches in the assessment of interferon‐alfa‐induced depression in patients with chronic hepatitis C – A critical review. Int. J. Methods Psychiatr. Res. 2007 16 4 186 201 10.1002/mpr.229 18188838
    [Google Scholar]
  64. Anisman H. Cascading effects of stressors and inflammatory immune system activation: Implications for major depressive disorder. J. Psychiatry Neurosci. 2009 34 1 4 20 [PMID: 19125209]. 19125209
    [Google Scholar]
  65. Udina M. Castellví P. Moreno-España J. Navinés R. Valdés M. Forns X. Langohr K. Solà R. Vieta E. Martín-Santos R. Interferon-induced depression in chronic hepatitis C: A systematic review and meta-analysis. J. Clin. Psychiatry 2012 73 8 1128 1138 10.4088/JCP.12r07694 22967776
    [Google Scholar]
  66. Hauser G. Awad T. Brok J. Thorlund K. Štimac D. Mabrouk M. Gluud C. Gluud L.L. Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C. Cochrane Libr. 2014 2014 2 CD005441 10.1002/14651858.CD005441.pub3 24585509
    [Google Scholar]
  67. Schaefer M. Sarkar R. Knop V. Effenberger S. Friebe A. Heinze L. Spengler U. Schlaepfer T. Reimer J. Buggisch P. Ockenga J. Link R. Rentrop M. Weidenbach H. Fromm G. Lieb K. Baumert T.F. Heinz A. Discher T. Neumann K. Zeuzem S. Berg T. Escitalopram for the prevention of peginterferon-α2a-associated depression in hepatitis C virus-infected patients without previous psychiatric disease: A randomized trial. Ann. Intern. Med. 2012 157 2 94 103 10.7326/0003‑4819‑157‑2‑201207170‑00006 22801672
    [Google Scholar]
  68. Hou X.J. Xu J.H. Wang J. Yu Y.Y. Can antidepressants prevent pegylated interferon-α/ribavirin-associated depression in patients with chronic hepatitis C: Meta-analysis of randomized, double-blind, placebo- controlled trials? PLoS One 2013 8 10 e76799 10.1371/journal.pone.0076799 24204676
    [Google Scholar]
  69. Rusu A. Munteanu A.C. Arbănași E.M. Uivarosi V. Overview of side-effects of antibacterial fluoroquinolones: New drugs versus old drugs, a step forward in the safety profile? Pharmaceutics 2023 15 3 804 10.3390/pharmaceutics15030804 36986665
    [Google Scholar]
  70. Bennett A.C. Bennett C.L. Witherspoon B.J. Knopf K.B. An evaluation of reports of ciprofloxacin, levofloxacin, and moxifloxacin-association neuropsychiatric toxicities, long-term disability, and aortic aneurysms/dissections disseminated by the food and drug administration and the European medicines agency. Expert Opin. Drug Saf. 2019 18 11 1055 1063 10.1080/14740338.2019.1665022 31500468
    [Google Scholar]
  71. Tomé A.M. Filipe A. Quinolones. Drug Saf. 2011 34 6 465 488 10.2165/11587280‑000000000‑00000 21585220
    [Google Scholar]
  72. Ilgin S. Can O.D. Atli O. Ucel U.I. Sener E. Guven I. Ciprofloxacin-induced neurotoxicity: Evaluation of possible underlying mechanisms. Toxicol. Mech. Methods 2015 25 5 374 381 10.3109/15376516.2015.1026008 25902267
    [Google Scholar]
  73. Smalheiser N.R. Lugli G. Rizavi H.S. Torvik V.I. Turecki G. Dwivedi Y. MicroRNA expression is down-regulated and reorganized in prefrontal cortex of depressed suicide subjects. PLoS One 2012 7 3 e33201 10.1371/journal.pone.0033201 22427989
    [Google Scholar]
  74. Odebrecht Vargas H. Vargas Nunes S.O. Pizzo de Castro M. Cristina Bortolasci C. Sabbatini Barbosa D. Kaminami Morimoto H. Venugopal K. Dodd S. Maes M. Berk M. Oxidative stress and lowered total antioxidant status are associated with a history of suicide attempts. J. Affect. Disord. 2013 150 3 923 930 10.1016/j.jad.2013.05.016 23856278
    [Google Scholar]
  75. Samyde J. Petit P. Hillaire-Buys D. Faillie J.L. Quinolone antibiotics and suicidal behavior: Analysis of the World Health Organization’s adverse drug reactions database and discussion of potential mechanisms. Psychopharmacology 2016 233 13 2503 2511 10.1007/s00213‑016‑4300‑3 27113226
    [Google Scholar]
  76. Wolkowitz O. Prospective controlled studies of the behavioral and biological effects of exogenous corticosteroids. Psychoneuroendocrinology 1994 19 3 233 255 10.1016/0306‑4530(94)90064‑7 7515507
    [Google Scholar]
  77. Scott B.P. Jeanne V.A.W. Edgar J.L. Self-reported depressive symptoms in association with medication exposures among medical inpatients: A cross-sectional study. Can. J. Psychiatry 1995 40 5 264 269 10.1177/070674379504000508 7553546
    [Google Scholar]
  78. Gift A.G. Wood R.M. Cahill C.A. Depression, somatization and steroid use in chronic obstructive pulmonary disease. Int. J. Nurs. Stud. 1989 26 3 281 286 10.1016/0020‑7489(89)90009‑6 2767912
    [Google Scholar]
  79. Brown E.S. Chandler P.A. Mood and cognitive changes during systemic corticosteroid therapy. Prim. Care Companion J. Clin. Psychiatry 2001 3 1 17 21 10.4088/pcc.v03n0104 15014624
    [Google Scholar]
  80. Ou G. Bressler B. Galorport C. Lam E. Ko H.H. Enns R. Telford J. Schaffer N. Lee T. Rosenfeld G. Rate of corticosteroid-induced mood changes in patients with inflammatory bowel disease: A prospective study. J. Can. Assoc. Gastroenterol. 2018 1 3 99 106 10.1093/jcag/gwy023 31294728
    [Google Scholar]
  81. Ali S. Paul S. Yakkali S. Teresa Selvin S. Thomas S. Bikeyeva V. Abdullah A. Radivojevic A. Abu Jad A.A. Ravanavena A. Ravindra C. Igweonu-Nwakile E.O. Hamid P. Glucocorticoids-induced neuropsychiatric disorders in patients with inflammatory bowel disease: A systematic review. Cureus 2022 14 9 e28981 10.7759/cureus.28981 36225410
    [Google Scholar]
  82. Toffol E. Heikinheimo O. Koponen P. Luoto R. Partonen T. Hormonal contraception and mental health: Results of a population-based study. Hum. Reprod. 2011 26 11 3085 3093 10.1093/humrep/der269 21840911
    [Google Scholar]
  83. Toffol E. Heikinheimo O. Koponen P. Luoto R. Partonen T. Further evidence for lack of negative associations between hormonal contraception and mental health. Contraception 2012 86 5 470 480 10.1016/j.contraception.2012.02.014 22465115
    [Google Scholar]
  84. Skovlund C.W. Mørch L.S. Kessing L.V. Lidegaard Ø. Association of Hormonal Contraception With Depression. JAMA Psychiatry 2016 73 11 1154 1162 10.1001/jamapsychiatry.2016.2387 27680324
    [Google Scholar]
  85. Kraft M.Z. Rojczyk P. Weiss T. Derntl B. Kikinis Z. Croy I. Heller C. Symptoms of mental disorders and oral contraception use: A systematic review and meta-analysis. Front. Neuroendocrinol. 2024 72 101111 10.1016/j.yfrne.2023.101111 37967755
    [Google Scholar]
  86. Anderl C. Li G. Chen F.S. Oral contraceptive use in adolescence predicts lasting vulnerability to depression in adulthood. J. Child Psychol. Psychiatry 2020 61 2 148 156 10.1111/jcpp.13115 31461541
    [Google Scholar]
  87. Anderl C. de Wit A.E. Giltay E.J. Oldehinkel A.J. Chen F.S. Association between adolescent oral contraceptive use and future major depressive disorder: A prospective cohort study. J. Child Psychol. Psychiatry 2022 63 3 333 341 10.1111/jcpp.13476 34254301
    [Google Scholar]
  88. Robakis T. Williams K.E. Nutkiewicz L. Rasgon N.L. Hormonal contraceptives and mood: Review of the literature and implications for future research. Curr. Psychiatry Rep. 2019 21 7 57 10.1007/s11920‑019‑1034‑z 31172309
    [Google Scholar]
  89. Berry-Bibee E.N. Kim M.J. Simmons K.B. Tepper N.K. Riley H.E.M. Pagano H.P. Curtis K.M. Drug interactions between hormonal contraceptives and psychotropic drugs: A systematic review. Contraception 2016 94 6 650 667 10.1016/j.contraception.2016.07.011 27444984
    [Google Scholar]
  90. FDA requires stronger warning about risk of neuropsychiatric events associated with asthma and allergy medication singulair and generic montelukast. 2020 Available from: www.fda.gov/news-events/press-announcements/fda-requires-stronger-warning-about-risk-neuropsychiatric-events-associated-asthma-and-allergy
  91. Lo C.W.H. Pathadka S. Qin S.X. Fung L.W.Y. Yan V.K.C. Yiu H.H.E. Bloom C.I. Wong I.C.K. Chan E.W.Y. Neuropsychiatric events associated with montelukast in patients with asthma: A systematic review. Eur Respir Rev 2023 32 169 230079 10.1183/16000617.0079‑2023
    [Google Scholar]
  92. Glockler-Lauf S.D. Finkelstein Y. Zhu J. Feldman L.Y. To T. Montelukast and neuropsychiatric events in children with Asthma: A nested case–control study. J. Pediatr. 2019 209 176 182.e4 10.1016/j.jpeds.2019.02.009 30905424
    [Google Scholar]
  93. Benard B. Bastien V. Vinet B. Yang R. Krajinovic M. Ducharme F.M. Neuropsychiatric adverse drug reactions in children initiated on montelukast in real-life practice. Eur. Respir. J. 2017 50 2 1700148 10.1183/13993003.00148‑2017 28818882
    [Google Scholar]
  94. Yilmaz Bayer O. Turktas I. Ertoy Karagol H.I. Soysal S. Yapar D. Neuropsychiatric adverse drug reactions induced by montelukast impair the quality of life in children with asthma. J Asthma 2022 59 3 580 589 10.1080/02770903.2020.1861626
    [Google Scholar]
  95. Ali M.M. O’Brien C.E. Cleves M.A. Martin B.C. Exploring the possible association between montelukast and neuropsychiatric events among children with asthma: A matched nested case‐control study. Pharmacoepidemiol. Drug Saf. 2015 24 4 435 445 10.1002/pds.3758 25683909
    [Google Scholar]
  96. Al-Amran F.G. Hadi N.R. Hashim A.M. Cysteinyl leukotriene receptor antagonist montelukast ameliorates acute lung injury following haemorrhagic shock in rats. Eur J Cardiothorac Surg 2013 43 2 421 427 10.1093/ejcts/ezs312
    [Google Scholar]
  97. Sansing-Foster V. Haug N. Mosholder A. Cocoros N.M. Bradley M. Ma Y. Pennap D. Dee E.C. Toh S. Pestine E. Petrone A.B. Kim I. Lyons J.G. Eworuke E. Risk of psychiatric adverse events among montelukast users. J. Allergy Clin. Immunol. Pract. 2021 9 1 385 393.e12 10.1016/j.jaip.2020.07.052 32795564
    [Google Scholar]
  98. Bremner J.D. Fani N. Ashraf A. Votaw J.R. Brummer M.E. Cummins T. Vaccarino V. Goodman M.M. Reed L. Siddiq S. Nemeroff C.B. Functional brain imaging alterations in acne patients treated with isotretinoin. Am. J. Psychiatry 2005 162 5 983 991 10.1176/appi.ajp.162.5.983 15863802
    [Google Scholar]
  99. Huang Y.C. Cheng Y.C. Isotretinoin treatment for acne and risk of depression: A systematic review and meta-analysis. J. Am. Acad. Dermatol. 2017 76 6 1068 1076.e9 10.1016/j.jaad.2016.12.028 28291553
    [Google Scholar]
  100. Li C. Chen J. Wang W. Ai M. Zhang Q. Kuang L. Use of isotretinoin and risk of depression in patients with acne: A systematic review and meta-analysis. BMJ Open 2019 9 1 e021549 10.1136/bmjopen‑2018‑021549 30670500
    [Google Scholar]
  101. Abdelmaksoud A. Vojvodic A. Ayhan E. Dönmezdil S. Jovicevic T.V. Vojvodic P. Lotti T. Vestita M. Depression, isotretinoin, and folic acid: A practical review. Dermatol. Ther. 2019 32 6 e13104 10.1111/dth.13104 31587447
    [Google Scholar]
  102. Fard N.M. Faghihi G. Mokhtari F. Motamedi N. Hosseini S. Comparing the efficacy of low dose and conventional dose of oral isotretinoin in treatment of moderate and severe acne vulgaris. J. Res. Pharm. Pract. 2017 6 4 233 238 10.4103/jrpp.JRPP_17_30 29417084
    [Google Scholar]
  103. Hyman S.E. The diagnosis of mental disorders: The problem of reification. Annu. Rev. Clin. Psychol. 2010 6 1 155 179 10.1146/annurev.clinpsy.3.022806.091532 17716032
    [Google Scholar]
  104. Lu D. Andersson T.M.L. Fall K. Hultman C.M. Czene K. Valdimarsdóttir U. Fang F. Clinical diagnosis of mental disorders immediately before and after cancer diagnosis. JAMA Oncol. 2016 2 9 1188 1196 10.1001/jamaoncol.2016.0483 27124325
    [Google Scholar]
/content/journals/cprr/10.2174/0126660822361079250329171531
Loading

  • Article Type:     Review Article
Keywords: Drug-induced mental disorders ; pharmacovigilance ; depression ; suicidal behavior

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test